Cognitive impairment six months after ischaemic stroke: a profile from the ASPIRE-S study by unknown
Mellon et al. BMC Neurology  (2015) 15:31 
DOI 10.1186/s12883-015-0288-2RESEARCH ARTICLE Open AccessCognitive impairment six months after ischaemic
stroke: a profile from the ASPIRE-S study
Lisa Mellon1*, Linda Brewer2, Patricia Hall2, Frances Horgan3, David Williams2, Anne Hickey1 and on behalf of the
ASPIRE-S study groupAbstract
Background: Cognitive impairment commonly occurs in the acute phase post-stroke, but may persist with over
half of all stroke survivors experiencing some form of long-term cognitive deficit. Recent evidence suggests that
optimising secondary prevention adherence is a critical factor in preventing recurrent stroke and the incidence of
stroke-related cognitive impairment and dementia. The aim of this study was to profile cognitive impairment of
stroke survivors at six months, and to identify factors associated with cognitive impairment post-stroke, focusing on
indicators of adequate secondary prevention and psychological function.
Methods: Participants were assessed at six months following an ischaemic stroke as part of the Action on
Secondary Prevention Interventions and Rehabilitation in Stroke study (ASPIRE-S), which examined the secondary
preventive and rehabilitative profile of patients in the community post-stroke. Cognitive impairment was measured
using the Montreal Cognitive Assessment (MoCA).
Results: Two-hundred and fifty-six stroke patients were assessed at six months. Over half of the sample (56.6%)
were found to have cognitive impairment, with significant associations between cognitive impairment and female
sex (odds ratio (OR) = 1.6, 95% CI 1.01-2.57) and history of cerebrovascular disease (OR = 2.22, 95% CI 1.38-3.59).
Treatment with antihypertensive medications (OR = .65, 95% CI .44-.96) and prescription of anticoagulant therapy
(OR = .41, 95% CI .26-.68) were associated with reduced likelihood of cognitive impairment, however increasing
number of total prescribed medications was moderately associated with poorer cognitive impairment (OR = 1.12,
95% CI 1.04-1.19).
Conclusions: Findings reveal levels of cognitive impairment at 6 months post-stroke that are concerning. Encouragingly,
aspects of secondary prevention were identified that may be protective in reducing the incidence of cognitive
impairment post-stroke. Neuropsychological rehabilitation post-stroke is also required as part of stroke rehabilitation
models to meet the burden of post-stroke cognitive impairment.
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Stroke is the second most common cause of death in the
world after ischaemic heart disease [1] and the leading
cause of acquired disability, with over half of patients
remaining physically dependent following a stroke [2]
and approximately two-thirds having some form of
neurological impairment at five years post-stroke [3].
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unless otherwise stated.researched, with evidence demonstrating significant im-
provements following physical rehabilitation [4]. However
strategies for restoration of cognitive dysfunction receive
significantly less attention with cognitive rehabilitation
post-stroke arguably the “lost dimension” of stroke re-
habilitation. Estimation of the prevalence of post-stroke
cognitive impairments is difficult given the range of poten-
tial deficits, including memory, attention, and visuospatial
ability, thus reported rates have varied from 30-50% [5]. A
degree of cognitive impairment is often evident in the im-
mediate aftermath of stroke with many deficits resolving
over the initial recovery period [6]. However longitudinalThis is an Open Access article distributed under the terms of the Creative
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long-term prevalence of cognitive impairment in stroke,
with prevalence rates of 22% at five years and 21% at
14 years reported, highlighting the persistent pervasive-
ness of cognitive deficits. Cognitive impairment can have a
significant impact on quality of life and activities of daily
living by reducing the degree of independence of the indi-
vidual [8] and is associated with long-term morbidity and
disability [7].
Up to 34% of patients with dementia show significant
vascular pathology [9]. Because vascular risk factors are
treatable and, in some instances preventable, it may be
possible to prevent, postpone, or mitigate vascular cog-
nitive impairment (VCI), as well as the vascular exacer-
bation of Alzheimer’s disease. In a systematic review and
meta-analysis, Pendlebury and Rothwell [5] showed that
10% of patients had dementia before first stroke, 10%
developed dementia in the year after first stroke and
over one-third of patients developed dementia after re-
current stroke. Emerging evidence suggests that appro-
priate secondary prevention of recurrent events may
reduce the burden of post-stroke cognitive impairment
and progression to dementia. The Perindopril Protection
against Recurrent Stroke Study (PROGRESS) rando-
mised clinical trial reported that active blood pressure
management was associated with a 19% risk reduction in
cognitive decline [10]. A recent UK study [11] also sug-
gested that appropriate management of vascular risk fac-
tors post-stroke was associated with longer term
protective benefits for onset of cognitive impairment. In
particular, management of vascular risk factors, includ-
ing adequate blood pressure control, lipid control and
anti-thrombotic therapy were associated with reduced
risk of post-stroke cognitive impairment over a 15 year
follow-up period.
The cognitive profile of Irish stroke survivors at six
months was examined as part of the Action on Second-
ary Prevention Interventions and Rehabilitation in
Stroke study (ASPIRE-S). The ASPIRE-S study was a
prospective descriptive study which aimed to address
three components of stroke care following discharge
from acute hospital care, namely secondary preventive
strategies, delivery of community rehabilitative care and
ongoing rehabilitative need. The aim of the analysis pre-
sented in this study was to comprehensively profile post-
stroke cognitive impairment and, in doing so, to deter-
mine which factors were associated with cognitive im-
pairment in this stroke survivor cohort.
Methods
Study population and procedure
The ASPIRE-S participants were consecutively recruited
first ever and recurrent stroke cases in patients of all
ages admitted to three large teaching hospitals betweenOctober 1st 2011 and September 30th 2012. The North
Dublin Population Stroke Study group (NDPSS) [12-14]
has previously characterised the stroke population in
North Dublin, providing detailed clinical information on
incidence and clinical profile of stroke patients in this
geographical area of Ireland. The study received ethical
approval from the Research Ethics Committees of the
three participating hospitals. Participants consented to
participate in ASPIRE-S whilst in hospital with an acute
stroke, with assent from next-of-kin obtained for pa-
tients identified by the medical team as lacking capacity
to give informed consent. In-hospital recruitment was
conducted by the research team which included a car-
diovascular research nurse, a clinical research fellow and
research assistant across the three hospital sites. Con-
sented participants were contacted at six months post-
stroke to participate in a detailed assessment of second-
ary preventive and rehabilitative indicators. The assess-
ment by a member of the research team took place
either in the participant’s home or in dedicated clinical
research facilities at one of the participating hospitals,
depending on the participant’s preference.
The study focused on hospital-based case ascertainment,
as NDPSS found that over 90% of stroke cases were
treated in an acute hospital [12]. Case ascertainment was
identified by daily review of referrals to the neurology,
geriatric and stroke consultation services for each of the
participating hospital sites. The World Health Organisa-
tion (WHO) definition of stroke was used to define pre-
senting stroke as “rapidly developing clinical signs of focal
or global disturbance of cerebral function, lasting more
than 24 hours or leading to death with no apparent cause
other than that of vascular origin” [15]. Participants were
excluded if the following criteria were identified: diagnosis
of subarachnoid haemorrhage, intracerebral haemorrhage
or sub-dural and extra-dural haematoma; transient ischae-
mic attack (TIA); residence outside the geographic area
defining the source population; age < 18 years.
Measures
Baseline assessment
Demographic and baseline clinical characteristics were re-
corded for each participant during in-hospital recruitment
including age, sex, cardiovascular risk factors, stroke sever-
ity (Scandinavian Stroke Scale (SSS) [16] and stroke sub-
type using the Bamford classification [17] and TOAST cri-
teria for stroke aetiology [18]. Pre-stroke functional de-
pendency was assessed retrospectively and at 72 hours,
using the Modified Rankin Scale (mRS) [19], a commonly
used measure of global disability used as a functional out-
come measure in stroke populations [20]. All members of
the team received standardised training in the administra-
tion of all assessment measures to minimise measurement
variability.
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Ongoing rehabilitative need and functional dependency
A number of assessments were performed to assess level
of disability and rehabilitative need.
1. Cognitive function was assessed using the Montreal
Cognitive Assessment (MoCA) [21]. The MoCA was
developed for use in the detection of Mild Cognitive
Impairment (MCI), and screens for the common
domains of impairment in MCI. Short-term memory
recall, delayed recall, visuospatial abilities, executive
functions, phonemic and syntactic fluency, verbal
abstraction, serial subtraction, attention, concentration
and working memory and orientation to time and
place are all examined in a 30-point test which can be
administered in approximately 10 minutes [21]. The
original MoCA publication sets the cut-off threshold
for cognitive impairment as a MoCA score of less
than 26. The MoCA has been reported as a valid
measure for screening for cognitive impairment and
dementia in stroke cohorts [22], demonstrating higher
sensitivity than the Mini Mental State Examination
(MMSE), at the cost of lower specificity [22,23].
2. Functional status was assessed using the Modified
Rankin Scale (mRS) [20] with higher scores
indicating greater functional impairment.
3. Psychological function was assessed using a number
of measures included in a self-completion question-
naire which was posted to participants in the week
preceding the ASPIRE-S assessment. The Hospital
Anxiety and Depression Scale (HADS) was included
in the self-completion questionnaire, a widely used
scale for assessment of mood disorder, containing
two dimensions for anxiety and depression [24]. The
range of scores for each dimension is 0–21, with a
score of greater than 7 indicative of probable or
possible presence of symptoms of mood disorder
[25]. The HADS has been validated for use in stroke
cohorts [26]. The Vulnerable Elders Scale (VES) was
also completed by the participant as part of the
self-completion questionnaire. The VES is a 13-item
measure, with scores greater than a cut-off of 3
indicating vulnerability and increased risk for
mortality in the subsequent two years [27]. Post-stroke
health-related quality of life (HRQoL) was assessed
using the Stroke Specific Quality of Life Scale (SSQoL)
[28], a 35-item scale which examines seven domains of
quality of life, namely physical function, mood, role
function, vision, language, thinking and energy. The
maximum score is 175, with higher scores indicating
better self-reported HRQoL.
The HADS, VES and SSQoL were included in a postal
questionnaire which stroke survivors received one weekprior to the ASPIRE-S home assessment. During the
ASPIRE-S home assessment, participants were provided
with the opportunity to clarify any questions presented
in the questionnaire, and ASPIRE-S researchers ensured
completeness of the questionnaire.
Secondary prevention
A number of clinical efficacy markers were recorded dur-
ing the six-month assessment, including resting blood
pressure using a digital OMRON M6 (Intellisense™) Dual
Check System, International Normalised Ratio (INR) con-
trol (average of last three INR readings) medications, medi-
cation adherence, and carbon monoxide assessment for
participants documented as smokers at baseline. Pharmaco-
logical secondary prevention was examined through fasting
venous blood analysis of serum total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein
cholesterol, triglycerides, fasting glucose and HbA1c (dia-
betics only). All participants were fitted with a 24-hour am-
bulatory blood pressure monitor where possible.
Statistical analysis
Descriptive statistics and non-parametric comparisons
using χ2 test and Fisher’s Exact test for categorical vari-
ables and Kruskal Wallis test for continuous variables
were used to examine the association between cognitive
impairment (MoCA <26) and demographic and clinical
characteristics. The degree of association between indi-
vidual variables and cognitive impairment was estimated
using the odds ratio (OR) and 95% confidence interval
(CI). Multivariable analysis was adjusted for age, sex and
stroke severity as these variables are highly correlated
with stroke outcome [29]. Considerations for modelling
sample size were applied to avoid over-fitting of the
models and subsequent production of biased estimates
of effect size [30,31]. Statistical analysis using the cluster
option in Stata 12.0 provided Huber-White-robust stand-
ard error estimates as data were collected across three dif-
fering hospital sites. Targets for secondary preventive
indicators (blood pressure, glucose, cholesterol) were cal-
culated using the European guidelines on cardiovascular
disease prevention in clinical practice 2012 [32] and rec-
ommendations from the EUROASPIRE III stroke study
[33]. Raised blood pressure was defined as systolic blood
pressure ≥140 mmHg and or diastolic blood pressure
≥90 mmHg. Raised cholesterol levels were defined as total
cholesterol concentration ≥4.5 mmol/L, and/or LDL chol-
esterol ≥2.5 mmol/L, and impaired fasting glycaemia was
defined as fasting glucose <7 mmol/L [33].
Results
Three hundred and two stroke cases were recruited to
the ASPIRE-S study at baseline. Approximately 52% of
all referred cases were ineligible for study inclusion at
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inclusion recorded as patient diagnosed as TIA follow-
ing MRI imaging (17.9%), or too medically unwell dur-
ing hospital admission (16%). Of the 302 stroke cases
recruited at baseline, 256 assessments were completed
at six months post-stroke (84.8%). Reasons for non-
completion of follow-up were death in preceding six
months (n = 9), declined participation (n = 22), develop-
ment of serious illness (n = 6), final discharge diagnosis
as not stroke (n = 4) and uncontactable (n = 5). The
mean age was 69 years (±12.9; median 71 years, IQR =
61-78) at time of stroke onset, with 96.4% of patients
functionally independent prior to the stroke, defined by
mRS <3. Median stroke severity score on the SSS was
52 (IQR 45–58). Prevalence of functional dependence at
six months post stroke (mRS ≥3) was 30.8% (N = 79), re-
duced from 47.5% (n = 121) at 72 hours post-stroke.
Cognitive performance at six months
MoCA assessment was completed for 226/256 partici-
pants (88.2%). The mean MoCA score was 23.5 (SD ±
4.9), with scores ranging from 7 to 30. Performance on
each of the MoCA sub-domains and associated confi-
dence intervals are presented in Table 1. Poorest per-
formance was evident in recall (Mean = 2.53; SD ± 1.6;
range 0–5), and visuospatial and executive functioning
(Mean = 3.53; SD ± 1.5; range 0–5). When the standard
MoCA cut-off of <26 for cognitive impairment was ap-
plied to the sample, 128 participants (56.6%) scored in
the impaired range on MoCA at six months post-stroke.
A higher proportion of females were categorised as cog-
nitively impaired. The presence of a number of risk fac-
tors had an association with cognitive impairment in
univariate analysis, namely history of a previous cerebro-
vascular event, atrial fibrillation and carotid stenosis (See
Table 2). The burden of cognitive impairment was fur-
ther explored by lowering the threshold for cognitive im-
pairment on MoCA scoring to <23 [23]. The prevalence
of cognitive impairment in the sample using this cut-offTable 1 Mean domain scores for MoCA




Naming 0-3 2.62 2.52-2.72
Attention 0-6 5.23 5.06-5.40
Language 0-3 2.22 2.10-2.34
Abstraction 0-2 1.72 1.64-1.79
Delayed recall 0-5 2.53 2.32-2.74
Orientation 0-6 5.65 5.54-5.76
Total MoCA score 0-30 23.53 22.88-24.18
CI, Confidence Interval.was 92/226 (41%), indicating a pervasive level of impair-
ment in the sample.
The association between sex and presence of cognitive
impairment was modestly attenuated in multivariable ana-
lysis adjusted for age and stroke severity, with women
more likely to have cognitive impairment than men (OR =
1.6, 95% CI 1.01-2.57). History of a previous cerebrovascu-
lar event was also related to an increased likelihood of
cognitive impairment (OR = 2.2, 95% CI1.38-3.59). Poster-
ior circulation (OR = 1.86, 95% CI 1.84-1.89) and lacunar
strokes (OR = 1.72, 95% CI 1.38-2.14) were also more
likely to score in the impaired MoCA range when adjust-
ing for age and stroke severity (See Table 3).
Key secondary preventive targets were assessed for
their association with cognitive impairment (Table 4).
Increasing number of prescribed medications was associ-
ated with higher likelihood of presence of cognitive im-
pairment (OR = 1.12, 95% CI 1.04-1.19). Polytherapy
with >2 antihypertensive medications (OR 0.67, 95% CI
0.46-0.96) and an anticoagulant (OR = .41, 95% CI .26-
.68) were shown to have a protective effect for reduced
likelihood of cognitive impairment. Antiplatelet therapy
was also associated with protection against cognitive im-
pairment (OR = .38, 95% CI .13-1.11), however this effect
did not reach statistical significance (Table 4). A moder-
ate association was evident between uncontrolled total
cholesterol level and increased likelihood of cognitive
impairment (OR = 1.86, 95% CI .91-3.82), with the ob-
served p-value approaching statistical signifiance.
Measures of psychosocial well-being were assessed for
their relationship to cognitive impairment. Those identi-
fied as vulnerable on the VES, characterised by lower VES
scores, were more likely to have cognitive impairment at
6 months (β = −.39, p = 0.01, 95% CI -.58 - -.22). Better
quality of life on the self-reported SSQoL scale also was
associated with higher MoCA scores (β = .05, p < 0.001,
95% CI .03-.08). No relationship was found between scores
in the depressed or anxious range on HADS and cognitive
impairment (Table 5).
Discussion
This study profiled the prevalence of cognitive impair-
ment in a sample of Irish stroke survivors, and investi-
gated the relationship between cognitive impairment
and demographic, secondary preventive, clinical, and
psychosocial factors. Findings from this study indicate
that over 50% of patients exhibited cognitive impairment
six months post-stroke. This finding is similar to previ-
ous reported rates of cognitive impairment, which can
vary from approximately 30%-74% depending on follow-
up time and stroke subtype [34,35]. The six month
measurement window presented in this study can be
considered as relatively recent following stroke occur-
rence, however longitudinal findings from the South
Table 2 Demographic and clinical details at baseline and at six months for cognitively impaired and non-cognitively
impaired stroke survivors
Cognitive impairment No cognitive impairment
(n = 128; MoCA < = 25) (n = 98; MocA >26)
N (%) N (%) P value Univariate OR 95% CI
Age (Mean, ±SD) 71.8 (11.4) 63.2 (13.1) 0.001 1.06 1.02-1.09
Sex
Female 63 (67.7) 30 (32.3) <0.001 2.19 1.97- 2.45
Health Insurance status as proxy SES
Public patient 102 (65.8) 53 (34.2)
Private patient 26 (36.6) 45 (63.4) 0.001 .33 .14-.63
Baseline risk factors
Previous TIA/Stroke 41 (74.5) 14 (25.5) <0.001 2.83 1.6-4.9
Heart disease 42 (63.6) 24 (36.4) 0.91 1.5 .63-3.6
Hypertension 76 (60.3) 50 (39.7) 0.055 1.4 .99-1.98
Diabetes 24 (64.9) 13 (35.1) 0.059 1.5 .98-2.31
Hypercholesterolemia 65 (58.6) 46 (41.4) 0.23 1.16 .91-1.49
Smoker 34 (52.3) 31 (47.7) 0.18 .78 .54-1.12
Atrial fibrillation 53 (63.9) 30 (36.1) <0.001 1.6 1.26-1.04
Carotid stenosis 21 (61.8) 13 (38.9) <0.001 1.28 1.14-1.45
Bamford classification
TACS 6 (66.7) 3 (33.3) 0.67 1.56 .21-11.63
PACS 51 (55.4) 41 (44.6) 0.7 .92 .1-1.4
POCS 36 (53.7) 31 (46.3) <0.001 .84 .77-.92
LACS 33 (62.2) 20 (37.8) 0.002 1.35 1.12-1.64
TOAST classification
Large artery atherosclerosis 19 (52.8) 17 (47.2) 0.54 .83 .46-1.49
Cardioembolism 52 (59.8) 35 (40.2) 0.22 1.23 .88-1.72
Small vessel occlusion 12 (42.9) 16 (57.1) <0.001 .53 .45-.63
Other determined aetiology 4 (30.8) 9 (68.2) <0.001 .31 .23-.45
Undetermined aetiology 41 (66.1) 21 (33.9) 0.3 1.72 .61-4.89
Stroke severity (SSS scale; Median, IQR) 51 (42–57.5) 56 (49–58) <0.001 .92 .89-.94
Functional dependency
Pre-stroke function (mRS; Median, IQR) 0 (0–0) 0 (0–0) 0.02 2.07 1.08-3.95
Function at 72 hours (mRS; Median, IQR) 3 (1–4) 1 (0–3) <0.001 1.56 1.41-1.71
Function at six months 2 (1–3) 1 (1–2) <0.001 1.76 1.32-2.34
(mRS; Median, IQR)
VES (> = 3) 71 (73.2) 26 (26.8) 0.01 5.8 1.51-22.53
(n = 200)
HADS-D (>7) 24 (66.7) 12 (33.7) 0.16 2 .76-5.26
(n = 190)
HADS-A (>7) 27 (50.9) 26 (49.1) .98 0.95 .64-1.52
(n = 190)
SSQoL (Median, IQR) 135 (110–153) 152 (135–170) <0.001 0.97 .96-.98
(n = 173)
OR, odds ratio; CI, confidence interval; SD, standard deviation; SES, socioeconomic status; TIA, transient ischaemic attack; TACS, total anterior circulation stroke;
PACS, partial anterior circulation stroke; POCS, posterior circulation stroke; LACS, lacunar stroke; SSS, stroke severity; mRS, modified Rankin Scale; VES, Vulnerable
Elders Survey; HADS-D, Hospital Anxiety and Depression Scale- Depression; HADS-A, Hospital Anxiety and Depression Scale- Anxiety; SSQoL, Stroke Specific Quality
of Life.
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Table 3 Demographic and clinical factors associated with
cognitive impairment at 6 months post-stroke
Adjusted OR* P-value 95% CI
Sex (female) 1.6 0.05 1.01-2.57
Age 1.06 0.003 1.02-1.11
Stroke severity (SSS scale) .92 0.003 .88-.97
Insurance .23 0.002 .09-.59
History of TIA/Stroke 2.22 0.001 1.38-3.59
History of atrial fibrillation 1.06 0.83 .62-1.82
History of carotid stenosis .99 0.95 .76-1.29
POCS 1.86 <0.001 1.84-1.89
LACS 1.72 <0.001 1.38-2.14
Small artery occlusion .46 <0.001 .43-.5
Stroke of determined aetiology .99 1.00 .65-1.54
Stroke of undetermined aetiology 1.64 0.4 .51-5.2
Functional dependency at
6 months (mRS≥ 3)
1.06 0.83 .63-1.79
*adjusted for age, sex and stroke severity.
OR, odds ratio; CI, confidence interval; SSS, stroke severity; TIA, transient
ischaemic attack; POCS, posterior circulation stroke; LACS, lacunar stroke; mRS,
modified Rankin Scale.
Table 5 Psychological well-being factors associated with
cognitive impairment at 6 months post-stroke
Coefficient (β) P-value* 95% CI
Vulnerability (VES) -.39 0.01 -.58 - -.22
SSQoL .05 0.009 .03-.08
HADS-Depression .32 0.09 -.12-.76
HADS- Anxiety -.04 0.81 -.70-.62
*adjusted for age, sex and stroke severity.
OR, odds ratio; CI, confidence interval; VES, Vulnerable Elders Survey; SSQoL,
Stroke Specific Quality of Life Scale; HADS, Hospital Anxiety and
Depression Scale.
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prevalence of cognitive impairment, with a rate of 21%
evident up to 15 years post-stroke [7]. In this analysis,
females, those with a history of cerebrovascular disease
and those experiencing a posterior circulation or lacunar
infarct were most likely to exhibit cognitive impairment.
We also found that presence of cognitive impairment
was associated with increased likelihood of patient vul-
nerability and poorer quality of life. Given this high
prevalence of cognitive impairments post-stroke and its
contribution to dementia progression and poor psycho-
logical outcome, cognitive rehabilitation is a requiredTable 4 Secondary preventive factors associated with
cognitive impairment at 6 months post-stroke
Adjusted OR* P-value 95% CI
Blood pressure not at
target (>140/90)
1.02 0.93 .72-1.4
Fasting glucose not at
target <7 mmol/L)
1.11 0.73 .62-1.96
Serum total cholesterol not at
target (>4.5 mmol/L)
1.86 0.091 .91-3.82
Number of medications 1.12 0.001 1.04-1.19
Antihypertensive 1.22 0.44 .74-2.01
Polytherapy antihypertensive
(<2 vs. > = 2)
.67 0.03 .46-.96
Antiplatelet .38 0.078 .13-.68
Anticoagulant .41 <0.001 .26-.68
Statin .75 .59 .28-2.04
*adjusted for age, sex and stroke severity.
OR, odds ratio; CI, confidence interval.component of stroke rehabilitation. The current evi-
dence for the effectiveness of cognitive rehabilitation in
stroke is sparse, with very few studies using randomised
designs [36].
Findings from this study support emerging evidence for
the important role of secondary preventive strategies in
prevention of post-stroke cognitive decline and transitions
to dementia [5,11]. Results showed that polytherapy for
hypertension, i.e. taking two or more antihypertensive
medications, demonstrated a protective effect for the pres-
ence of cognitive impairment at six months post stroke.
Prescription of both anticoagulant and antihypertensive
therapies also demonstrated a protective effect, suggesting
that appropriate pharmacotherapy post-stroke may con-
tribute towards slowing of cognitive decline post-stroke in
addition to prevention of further stroke. Previous studies
have reported the protective association between optimal
risk factor control and reduced cognitive impairment, with
protective effects reported up to ten years post-stroke in a
UK population-based study [11]. There was an observed
trend in this analysis between uncontrolled total choles-
terol and the presence of cognitive impairment, although
did not reach statistical significance in this instance. This
relationship has been confirmed in previous studies. A
Finnish longitudinal cardiovascular risk factors study
found that mid-life serum cholesterol levels were associ-
ated with an increased risk of vascular dementia and Alz-
heimer’s disease in later life, even after adjustment for
statin therapy [37]. Serum cholesterol control is a key
component of basic secondary preventive strategies in car-
diovascular conditions, but still remains a challenge.
Interestingly, there appeared to be a relationship be-
tween prescribed complex medication regimens and
presence of cognitive impairment in this sample, with
greater numbers of prescribed medications related to
higher likelihood of cognitive impairment. Cognitive im-
pairment has been cited as a common barrier to success-
ful medication management in the elderly [38], and
polypharmacy in older populations is a known risk factor
for morbidity and mortality [39]. Important interactions
between polypharmacy, cognitive impairment and ad-
verse drug reactions have been reported in the literature
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understanding on behalf of the patient, thus as the com-
plexity of the regimen is increased, so also is the burden
on the patient [41]. Managing a complex medication
regimen whilst exhibiting signs of post-stroke cognitive
impairment is likely to increase the risk of non-
adherence, resulting in deleterious effects on secondary
prevention targets, further cognitive decline, substan-
tially increased risk of recurrent stroke, with its associ-
ated implications for subsequent dementia. Non-
adherence to medications has been found to be common
for patients with cardiovascular diseases, with a progres-
sive decline in adherence to prescribed secondary pre-
ventive medications evident with the passage of time
[42], and is associated with increased risk of morbidity
and mortality. In the context of stroke, cognitive impair-
ment is likely to interfere with patients’ capacity to ad-
here to their medication regimen.
The NICE guidelines recommend that each stroke pa-
tient should receive cognitive screening, regardless of
stroke severity, within 6 weeks of their stroke, in order
to identify cognitive deficits, including higher level im-
pairments that may impede normal activities of daily liv-
ing [43]. Evaluation of current practices for assessment
of cognitive impairment in the in the UK revealed that
up to 85% of healthcare professionals routinely screen
for cognitive impairment, however significant heterogen-
eity exists in method of assessment [44]. Little Irish data
exists to demonstrate that post-stroke cognition is rou-
tinely tested, and the Irish National Cardiovascular
Health Policy has highlighted that the lack of inclusion
of cognitive rehabilitation as part of standard stroke re-
habilitation is of prominent concern [41]. A lack of
standardisation in definition, evaluation and the timing
of assessment for post-stroke cognitive impairment ex-
ists [45]. The MoCA in particular is subject to ongoing
debate. It is argued that the universal cut-off score of
less than 26 may over diagnose the existence of true
cognitive impairment [46], and cut-offs of less than 23
have been suggested as having better clinical utility in
stroke [46,47]. Its brevity is useful in the context of
stroke where patient fatigue may be prevalent, however,
it is a brief screening tool for mild cognitive impairment
(MCI) and therefore does not capture all post-stroke
deficits. In-depth neuropsychological testing, such as the
NINDS [48], which accounts for a wide range of poten-
tial deficits and abilities is a recommended form of as-
sessment [48].
Limitations
The study was an observational cohort study, with no
matched non-stroke group available for comparison of
cognitive outcomes. Cognitive impairment was mea-
sured at only one time point during the stroke recoveryperiod, and pre-stroke cognitive function was not mea-
sured. Although the observed prevalence of impairment
at six months was high, pre-existing cognitive decline
may have been evident in some cases, given the age pro-
file of the sample and the finding that a quarter of the
sample had experienced a previous cerebrovascular
event. It is suggested that a measure such as the Inform-
ant Questionnaire for Cognitive Decline in the Elderly
(IQCODE) [49] be incorporated into research designs
were possible to capture an indicator of pre-stroke cog-
nitive function. Patients with TIA were excluded from
the present analysis. It has been demonstrated that ap-
proximately a third of patients with TIA can exhibit im-
pairment in at least one domain of cognitive function
following a TIA [50], therefore it may be important to
screen for cognitive changes in minor cerebrovascular
events in addition to confirmed stroke cases [51]. The
aim of this study was to provide as yet unknown data on
post-stroke cognitive impairment in an Irish cohort, and
focused on global cognitive impairment. Further explor-
ation of the relevance of impairments in different do-
mains for the development of appropriate rehabilitation
interventions is needed. Finally, the findings of study are
limited to stroke cases presenting to hospital. Population
studies in Ireland indicate that 90% of stroke cases are
treated in acute care, however those who do not present
to hospital may differ in stroke severity, and thus may
have very different cognitive outcomes. Future work
should attempt to capture outcomes for stroke cases
treated exclusively in the community.Conclusions
The predicted international population age profile shift
will result in more individuals at risk of stroke, an in-
creased burden on health and community services for
stroke, and a greater cost to national economies. This
paper reports findings from the ASPIRE-S study relating
to prevalence of cognitive impairment in a cohort of pa-
tients 6 months post-stroke, and found a high prevalence
of cognitive impairment six months post stroke. Address-
ing cognitive impairment is of significant importance, both
for the individual with stroke who is prevented from re-
suming engagement in normal life by impairments in cog-
nition, for patients’ families and for wider society who
ultimately support the care of those with post-stroke cog-
nitive impairment. Appropriate targeting of secondary
prevention control and specific cognitive rehabilitation
has the potential to prevent recurrent stroke and the pro-
gression from cognitive impairment to dementia in people
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